Global Regulatory Updates on Clinical Trials (March 2026)

March 2026 was a relatively light month for new clinical trial guidance publications across major global regulators. Activity was primarily driven by the U.S. Food and Drug Administration, which issued draft updates supporting more efficient biosimilar development and the integration of new approach methodologies. The European Medicines Agency contributed a draft guidance focused on maintaining trial continuity during public health emergencies.

However, the absence of new publications masks significant ongoing regulatory change. In China, the National Medical Products Administration is actively implementing major regulatory reforms and mandating adoption of ICH E6(R3) Good Clinical Practice, both of which substantially impact clinical trial design and conduct. Similarly, while the International Council for Harmonisation did not release new guidelines in March, the global rollout of E6(R3) continues to reshape trial oversight through risk-based and flexible approaches.

Other regulators, including the Therapeutic Goods Administration and Health Canada, remained active through ongoing initiatives and consultations but did not publish new clinical trial–specific guidance during this period.

U.S. Food and Drug Administration

Final updates

• No new final clinical trial–specific guidance published in March 2026

Draft updates

• New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 4)
  This draft guidance introduces updated recommendations on biosimilar development, including reduced requirements for clinical pharmacokinetic (PK) studies, acceptance of non-U.S. comparator products, and greater reliance on analytical data. These changes support more efficient clinical development and may reduce the need for certain Phase I–III studies.
• General Considerations for the Use of New Approach Methodologies in Drug Development (Draft Guidance)
  This draft guidance outlines the FDA’s expectations for integrating new approach methodologies (NAMs), such as in vitro and in silico models, into drug development. While primarily focused on nonclinical data, it has implications for early-phase clinical entry and may influence Phase I trial design and decision-making.

European Medicines Agency

Final updates

• No new final clinical trial guidance published in March 2026 affecting Phase I–IV drug and biologic trials.

Draft updates

• Draft Guidance on the Conduct of Clinical Trials During Public Health Emergencies
  Published under the ACT EU initiative, this draft guidance outlines regulatory flexibilities for initiating and managing clinical trials during public health emergencies. It includes provisions for accelerated approvals, decentralized trial approaches, and protocol adaptations while maintaining participant safety and data integrity across all phases.

National Medical Products Administration

Final updates

• No new clinical trial–specific guidance documents published in March 2026

Draft updates

• No draft clinical trial guidance identified in March 2026

Additional regulatory developments impacting clinical trials

• Implementation of revised Drug Administration Law regulations (issued January 2026)
  These introduce important changes affecting clinical development, including: 
  • Expanded acceptance of overseas clinical trial data
  • Acceleration pathways for drug approvals
  • Clarified requirements for sponsor changes and trial management
• Mandatory adoption of ICH E6(R3) Good Clinical Practice (effective March 31, 2026)
  All clinical trials in China must comply with updated GCP principles, including: 
  • Risk-based quality management
  • Increased flexibility in trial conduct (including decentralized elements)
  • Enhanced data governance expectations
• Policies to expedite approval of urgently needed overseas-marketed drugs (January 2026)
  These may reduce the need for local clinical trials in certain scenarios.

Therapeutic Goods Administration

Final updates

• No new clinical trial–specific guidance published in March 2026

Draft updates

• No draft updates identified in March 2026 for clinical trial regulations

Additional notes

• Routine regulatory activity (e.g., safety and product information updates) continued, but no new guidance directly affecting clinical trial design or conduct was issued during this period.

Health Canada

Final updates

• No new final clinical trial regulatory updates published in March 2026

Draft updates

• Modernizing the Clinical Trials Framework (Ongoing Consultation)
  Health Canada continues consultation on proposed updates to its clinical trials framework, introducing a lifecycle and risk-based regulatory approach. The proposed changes aim to improve flexibility, streamline approvals, and enhance oversight across all clinical phases.

International Council for Harmonisation

Final updates

• No new ICH guidelines finalized in March 2026 affecting Phase I–IV clinical trials

Draft updates

• No new draft ICH guidelines published in March 2026 impacting clinical trial design or conduct

Additional context

• Ongoing global implementation of ICH E6(R3) Good Clinical Practice (effective January 2026 in many regions) continues to significantly influence:
  • Risk-based trial oversight
  • Sponsor responsibilities
  • Data integrity and quality systems